| 000 | 01747 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516060224.0 | ||
| 264 | 0 | _c20120213 | |
| 008 | 201202s 0 0 eng d | ||
| 022 | _a1744-5078 | ||
| 024 | 7 |
_a10.3109/09273948.2011.603069 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDamato, Erika | |
| 245 | 0 | 0 |
_aPlasma exchange and rituximab in the management of acute occlusive retinal vasculopathy secondary to systemic lupus erythematosus. _h[electronic resource] |
| 260 |
_bOcular immunology and inflammation _cOct 2011 |
||
| 300 |
_a379-81 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLupus Vasculitis, Central Nervous System _xcomplications |
| 650 | 0 | 4 |
_aMethylprednisolone _xtherapeutic use |
| 650 | 0 | 4 |
_aMycophenolic Acid _xanalogs & derivatives |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 | _aPlasma Exchange |
| 650 | 0 | 4 |
_aPrednisolone _xtherapeutic use |
| 650 | 0 | 4 |
_aRetinal Artery Occlusion _xdrug therapy |
| 650 | 0 | 4 |
_aRetinal Vasculitis _xtherapy |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVisual Acuity _xdrug effects |
| 700 | 1 | _aChilov, Michael | |
| 700 | 1 | _aLee, Richard | |
| 700 | 1 | _aSingh, Anurag | |
| 700 | 1 | _aHarper, Stephen | |
| 700 | 1 | _aDick, Andrew | |
| 773 | 0 |
_tOcular immunology and inflammation _gvol. 19 _gno. 5 _gp. 379-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/09273948.2011.603069 _zAvailable from publisher's website |
| 999 |
_c21206727 _d21206727 |
||